Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program

Matthew Durham
Omnidynamic Marketing

Matt Turner
Patient Affordability

Suma Ramadas, PhD
Medical Affairs

Liz Kane
Impactful Strategy

Frank Burrell
Scientific Storytelling

Brenda Snow
Authentic Patient Voice

David Linetsky
Point-of-Care Marketing

Pat Purcell
Meeting Engagement

Stacey Gandler
Brand Nourishment

Joey Cohen
Medication Adherence

Daniel Sontupe
Market Access

Bud Bilanich
Success Coach

Paul Theisen
Patient Acquisition

Amy Giles
Increasing Engagement